Personlig profil

Mulige interessekonflikter

  • FADLs forlag (publisher): Author 4th edition of “Medicine” (textbook) - chapter on Multiple Endocrine Neoplasia
  • 2023 and 2024 2 lectures (1h each) sponsored by Novo Nordisk (NN). Topic not related to any NN medical products. 
  • Principal investigator phase 2 trial sponsored by MSD aiming to investigate safety and efficacy of Belzutifan in treatment of malignant pheochromocytoma and paraganglioms, 1st patient enrolled February 2022, altogether 5 patients enrolled, study ongoing (December 2024).
  • Principal investigator in a phase 1b trial sponsored by Debiopharma aiming to characterize the pharmacokinetics, pharmacodynamics, safety and tolerability of  a 12-week prolonged-release octreotide formulation in acromegalic patients - 2 acromegalic patients enrolled during 2022, last patient last visit summer 2024
  • Member of “Medicinrådet” for Endocrinology since 2022 and chair since 2024
  • Previous travel grants from Ipsen and Novartis, but not since 2019

 

Som klinisk lektor har jeg en dobbeltansættelse, der betyder, at jeg både er ansat i Region Hovedstaden og ved Københavns Universitet. For overblik over potentielle interessekonflikter henvises til min forskerprofil i regionen.

Samarbejde og topforskningsområder i de sidste fem år

Seneste eksterne samarbejde på lande-/områdeniveau. Dyk ned i detaljerne ved at klikke på prikkerne eller